the CXC and CC subfamilies. 3 Highlighting the importance of DARC to cytokine homoeostasis, a single nucleotide polymorphism (SNP) in DARC accounts for 20% of the variability in serum CCL2 in humans. 4 Despite the substantial role of DARC as a promiscuous regulator of inflammatory chemokines, its role in asthma is largely unknown.
A role for DARC in asthma pathophysiology was suggested by the association of a SNP in DARC with asthma prevalence in African descendants. 5 Although any causal link has yet to be determined, DARC is expressed on several cells relevant to asthma such as erythrocytes, lung endothelial cells, alveolar epithelial cells 6 and airway smooth muscle (ASM) cells. 7 Erythrocyte DARC internalizes circulating cytokines which prevents the interaction between cytokines and leucocytes. 8 In contrast, endothelial DARC promotes chemokine transcytosis and subsequent leucocyte migration into organs. 9 Although the function of DARC in airway epithelial cells is presently unclear, Darc expression is up-regulated in airway epithelium in response to acute airway inflammation. 10 Global ablation of Darc in mice reduced airway neutrophilia during acute lung injury; [11] [12] [13] however, whether DARC influences the severity of asthma, and by what mechanisms, has yet to be determined.
Due to the role of DARC in pro-inflammatory chemokine regulation and the contribution of other decoy receptors to resolution of inflammation, 14 we hypothesized that a loss of Darc function would exaggerate severe allergic airways disease and prolong resolution of pathophysiology. Therefore, we determined, in a mouse model of allergic airways disease, the effect of genetic deletion of DARC on the severity and resolution of asthma pathophysiology. In order to establish the clinical translatability of our findings to human asthma, we determined whether DARC single nucleotide polymorphisms (SNPs) were associated with clinical outcomes in a clinical trial of patients with severe asthma.
| MATERIALS AND METHODS

| Animals and animal study design
Mice in which a 90 bp region of the Darc gene locus had been eliminated from exon II and bred on a C57Bl\6J background (Darc ΔE2 mice) 15 were maintained as a breeding colony under pathogen-free conditions.
Deletion of the 90 kb region leads to loss of normal DARC mRNA expression and a substantially reduced affinity of erythrocytes to CXCL8
and CCL2. 15 Wild-type C57Bl\6J mice (WT) were purchased from Jackson Laboratories (Bar Harbor, ME, USA). Mice were studied at 8 weeks of age, and all experiments were approved by the Institutional Animal
Care and Use Committee at the University of Vermont (#11-029).
| House dust mite (HDM) antigen administration
Mice were administered 50 lg of intranasal HDM (Greer Laboratories, Lenoir, NC, USA) in sterile PBS (1 mg protein/mL) or PBS alone on 15 occasions over 3 weeks ( Figure 1A ). Mice were evaluated 24 hours or 7 days following the final instillation. Airway mechanics were assessed by the forced oscillation technique as Newtonian resistance, a measure of airway resistance, tissue damping, a measure of tissue resistance and tissue elastance, a measure of lung stiffness. 13 Lungs were lavaged with 1.0 mL of PBS and centrifuged at 12009g for 5 minutes to isolate cells. The pellet was re-suspended for total and differential cell counts and the supernatant used for quantification of cytokines.
Lung samples were taken for protein lysates, RNA extraction and analysis of collagen content. Additional methodological details are provided in the Supporting Information.
| Human genomic analyses
Eleven DARC SNPs (5%-15% frequency) were identified in the CEU cohort of the 1000 Genomes data set 16 available at www.1000genome
s.org (10 of which were present in our sample). A twelfth SNP, rs12075, was included due to its association with circulating proinflammatory cytokines. 4 Tag SNPs were interrogated by TaqMan genotyping in 169 poorly controlled White asthmatic patients who participated in the LODO ALA-ACRC clinical trial. 17 See Supporting Information for a description of the study population, prevalence of the analysed SNPs in the current population (Table S1 ) and schematic of the study design (Fig. S1 ). Clinical severity was assessed as contact with healthcare providers due to asthma (total contacts), unscheduled visits to asthma clinics and asthma control (ACQ
18
) and Asthma Symptom Utility Index, (ASUI 19 ). The study was approved by the Western Institutional Review Board, and local IRB approval was obtained from all individual sites. Written informed consent was obtained from all patients.
| Statistical analysis
Animal data were evaluated using two-or three-way ANOVA (AHR Figure 1D ).
| DARC promotes the resolution of HDMinduced neutrophilic airway inflammation
The increase in total leucocytes in BALF following HDM challenge did not differ between WT and Darc ΔE2 mice at either 24 hours or 7 days (Figure 2A) . Similarly, the increase in individual cell differentials following HDM challenge at either time-point did not differ between WT and Darc
ΔE2
. The exception was neutrophil levels at 7 days which were increased in Darc ΔE2 compared to WT mice suggesting that DARC contributes to the resolution of neutrophilic inflammation. and WT mice. The Th 1 -associated cytokine interferon-c did was not altered by HDM in either group. These findings suggest a Th 2 immune phenotype that was unaltered by DARC.
To determine the effect of DARC on chemokines levels during allergic airways disease, we measured chemokines in BAL which ) and low (CCL3, CCL4) DARC affinity. 3, 20 Although HDM increased BAL levels of CXCL10, CCL2 and CXCL9 at 24 hours these did not differ between WT and Darc ΔE2 mice (Fig. S3A ). In contrast, there were trends for increased CXCL1, CXCL2 and CCL5 at 24 hours in Darc ΔE2 mice; however, increased levels were also observed for CXCL1, CXCL2 and CCL2 in Darc ΔE2 PBS mice relative to WT mice (~twofold). Indeed, the significant genotype factor but non-significant interaction factor suggests that the increase in cytokines in Darc
mice was a consequence of increased baseline levels rather than an exaggerated response to HDM. These differences in cytokine levels were no longer apparent at 7 days, except a small increase in CXCL10
in HDM-challenged Darc ΔE2 mice (Fig. S3B ). Our human data reveals a complex and potentially important role for genetic alterations of DARC in the manifestation of asthma symptoms. In White poorly controlled asthmatics,~75% of which were prescribed ICS and LABA, rs12042349 was related to increased asthma symptoms at randomization. Importantly, the magnitude of the increase in ACQ associated with having one copy of rs12042349 was greater than the minimal clinically important difference. 21 Similarly, increased asthma symptoms as assessed by total contacts with healthcare providers due to asthma were associated with rs35333710 in those patients continuing on their pre-study treatment (ICS or ICS+LABA). In contrast, there was no association 
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Col 1a Surprisingly, the effect of DARC on pro-inflammatory cytokines did not translate into differences in overall airway inflammation.
However, this lack of effect of DARC status on total inflammation is consistent with findings in patients with acute lung injury 23 and endotoxemia. 25 There are conflicting reports from animal models as to the effect of DARC on airway inflammation following acute lung injury with both increased 15, 24 ways. 27 Despite no change in CXCR2 mRNA in Darc ΔE2 lung homogenates in the present study (data not shown), it is possible that reduced receptor competition led to increased chemokine binding with CXCR2 and thus delayed resolution of neutrophilia.
Our animal model provides important clues as to the mechanisms underlying the association between DARC SNPs and asthma symptoms in humans. Firstly, DARC is unlikely to affect asthma severity through effects on airway inflammation or immune phenotype.
Indeed, the effect on neutrophils was rather small and conflicts with previous findings suggesting that neutrophils promote AHR. 28, 29 Although recent in vitro findings suggest that loss of DARC promotes CXCL1-induced ASM proliferation, 7 we did not detect an effect of DARC on a-smooth muscle actin mRNA or any other markers of airway remodelling. Although we cannot rule out that the relatively short exposure period (3 weeks) may be insufficient to detect an effect of DARC on airway remodelling, we were able to detect an effect of AHR at this time-point. Furthermore, a lack of effect on airway remodelling is consistent with findings in other diseases associated with structural remodelling. 30, 31 In contrast, the loss of DARC function led to more severe AHR during peak allergen responses suggesting DARC may contribute to worse bronchoconstriction following allergen exposure. This is consistent with increased symptoms, assessed by questionnaire and healthcare utilization due to asthma, in patients with DARC SNPs. Although the exact mechanisms by which DARC alters AHR remain unknown, it is possible that they are mediated by increased chemokine levels. For example, CXCL1 has been shown to induce airway smooth muscle contraction 32 and promote mast cell recruitment to airway smooth muscle, 33 both of which could increase the extent of bronchoconstriction. However, further research is required to determine whether the loss of DARC alters airway smooth muscle function or contributes to AHR and asthma symptoms via other mechanisms.
The present study uniquely combines a murine model of allergic airways disease and a long-term clinical trial of severe asthmatics to examine the potential role of DARC in the temporal manifestation of asthma. Nonetheless, the present study does have some limitations.
Firstly, the LODO population was predominantly White and therefore underpowered to determine associations between clinical outcomes and DARC SNPs in Blacks. Therefore, findings cannot be generalized to Blacks in which DARC is known to be associated with asthma prevalence 5 and subsequent analyses specifically in this population are needed to determine the relevance of DARC SNPs on asthma symptoms in Blacks. As such, we did not include the predominant DARC SNP in Blacks, rs2814778, as its frequency in our population was 0%-0.5% in Whites and 70%-80% in Blacks. However, rs2814778 completely ablates erythrocyte DARC with no This SNP alters the level of DARC activity on erythrocytes and nonerythrocyte cells uniformly to produce three phenotypes of DARC activity; DARC which binds chemokines with "high activity", "moderate activity" (heterozygous) or "low activity". Thus, the global ablation of Darc in mice would seem to be most analogous to the "low activity" phenotype in Whites. While the effects of other DARC SNPs on DARC function are unknown, the present finding that DARC contributes to asthma severity is most likely only applicable to White patients with asthma.
Through a combination of animal and human data, we suggest that DARC plays a role in regulating the severity and resolution of asthma pathophysiology. Our findings in mice suggest that DARC alters the severity and resolution of AHR. These findings are complimented by our human analyses in which select DARC SNPs are associated with worse asthma control and symptoms. Interestingly, our data unveils an important gene-treatment interaction in which select DARC SNPs are associated to worse clinical outcomes only in patients prescribed ICS/LABA. Despite the underlying mechanisms remaining unclear, our study suggests that assessment of DARC status may provide the ability to discriminate those uncontrolled patients whom may gain the most benefit from alternative treatment strategies.
